Skip to main content
49°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
109.35
+0.95 (+0.88%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
Is NYSE:NVS suited for dividend investing?
November 01, 2024
Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS).
Via
Chartmill
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Novartis Reports Q3 Momentum, But Shares Lose Support
October 29, 2024
Novartis stock slipped Tuesday, despite a solid Q3 performance and an upgraded outlook.
Via
Investor's Business Daily
Looking Into Novartis's Recent Short Interest
October 14, 2024
Via
Benzinga
Why NYSE:NVS is a Top Pick for Dividend Investors.
October 09, 2024
Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.
Via
Chartmill
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
October 30, 2024
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.
Via
Benzinga
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
October 29, 2024
NVS earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook
October 29, 2024
Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.
Via
Benzinga
Topics
Earnings
Exposures
Financial
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
October 28, 2024
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.
Via
Investor's Business Daily
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
October 28, 2024
Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions.
Via
Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
September 13, 2024
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) provides a good dividend, while having solid fundamentals.
Via
Chartmill
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
These stocks are trading at less than 15 times their expected future profits.
Via
The Motley Fool
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
October 18, 2024
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...
Via
Benzinga
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
October 18, 2024
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European...
Via
Benzinga
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
October 17, 2024
Novartis is taking a more calculated and strategic approach to its growth.
Via
The Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales...
Via
Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
October 14, 2024
These companies have compelling track records.
Via
The Motley Fool
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm
October 10, 2024
OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting...
Via
Benzinga
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
October 03, 2024
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Via
Investor's Business Daily
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The Importance of Managing Bad Cholesterol: What You Should Know
September 27, 2024
(BPT) - Sponsored by Novartis Pharmaceuticals Corporation
Via
Brandpoint
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
September 18, 2024
Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...
Via
Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
September 11, 2024
Via
Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
September 11, 2024
Via
Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...
Via
Benzinga
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
September 05, 2024
Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.